Tonix Pharmaceuticals Holding 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Tanmaya net sales were approximately $15 million in the 3rd quarter, up 37% quarter over quarter; total prescriptions were 16,375, up 28% from the 2nd quarter.
- Tanmaya new prescriptions grew 17% quarter over quarter and refill prescriptions grew 56%; prescriptions for other FDA-approved fibromyalgia-indicated products were generally flat in the 3rd quarter.
- Net product revenue for the 3rd quarter ended September 30th, 2026 was approximately $17.2 million, comprising approximately $15 million from Tanmaya and $2.2 million from Zembrace SymTouch and Tosymra products, compared with $3.3 million in the same period in 2025.
- Cost of sales was approximately $1.3 million, compared with $1.4 million in the same period in 2025; research and development expenses were approximately $25.8 million, compared with $9.3 million, and selling, general and administrative expenses were approximately $45.6 million, compared with $25.7 million.
- Tonix ended the quarter with approximately $162.8 million in cash and cash equivalents, compared with approximately $207.6 million as of December 31st, 2025.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to Tonix Pharmaceuticals' third quarter 2026 financial results and business update conference call. At this time, all participants are on listen-only mode. Following management's prepared remarks, we will hold a question-and-answer session. As a reminder, this call is being recorded. I would now like to hand the call over to Deborah Elson, Head of Investor Relations at Tonix Pharmaceuticals.
Please go ahead. Thank you, operator, and good morning, everyone.
Thank you for joining us to discuss Tonix Pharmaceuticals' third quarter 2026 financial results and operational highlights. Before we begin, I would like to refer you to the forward-looking statements disclaimers on slide two. Any statements made on today's call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
These factors include, but are not limited to, risks related to the failure to successfully launch and commercialize TONMYA and any of our approved products, uncertainties of patent protection and litigation, risks related to the failure to obtain FDA clearances or approvals and non-compliance with FDA regulations, risks related to the timing and progress of clinical development of our product candidates, our need for additional financing, uncertainties of government or third-party payer reimbursement, limited research and development efforts and dependence upon third parties, and substantial competition. These risks are described more fully in our filings within the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2025, and our subsequent quarterly reports on Form 10-Q. Tonix undertakes no obligation to update or revise any forward-looking statements, except as required by law.
Joining me on today's call are Dr. Seth Lederman, Chief Executive Officer, Thomas Englese, Chief Commercial Officer, and Bradley Saenger, Chief Financial Officer. Following our prepared remarks, we will open the call for questions. With that, I will turn the call over to Seth.
Seth? Thank you, Deborah, and good morning, everyone.
Today, we are reporting our third quarter financial results and operational highlights. Slide three outlines our progress in advancing TONMYA's commercial business and priority clinical programs. TONMYA third quarter net sales totaled approximately $15 million, increasing 37% quarter-over-quarter. Previously signed payer agreements contributed to third quarter sales. We have also begun to see promising performance growth since our expanded sales force entered the field on September 1st. These positive trends are continuing into the fourth quarter. We remain encouraged by TONMYA's trajectory. With our larger sales force and growing sales, we believe we are well-positioned to create value by improving the treatment of fibromyalgia and reinvigorating this market. on October 1st, 2026, we received notice from Dr. Reddy's Laboratories that it had filed an Abbreviated New Drug Application, or ANDA, Paragraph IV patent certification for TONMYA.
Generic challenges are common in the life cycle of an approved drug. We will vigorously defend and enforce our TONMYA intellectual property rights against infringement. As we prioritize TONMYA's growth, we are also advancing key research and development programs. These include three programs. First, the potential pivotal phase II HORIZON study of TNX-102 SL for the treatment of major depressive disorder, or MDD, which could serve as a potential label expansion for TONMYA. Second, the phase II adaptive study of TNX-4800 for the prevention of Lyme disease. And third, the initiation of the phase II investigator-initiated study of TNX-1500, also known by its proposed name, mosdaprubart, to prevent kidney transplant rejection. I will now turn the call over to Thomas Englese, our Chief Commercial Officer, to discuss the TONMYA launch.
Tom? Thank you, Seth, and good morning, everyone.
I am honored to serve as Tonix's first Chief Commercial Officer, and I am grateful to our team for their hard work. On slide four, net sales of TONMYA were approximately $15 million in the third quarter, representing 37% quarter-over-quarter growth. Key contributors included pull-through from the two commercial payer agreements signed in May and June, more favorable gross-to-net adjustments than expected, and execution of our launch strategy. We continue to expect gross-to-net fluctuations early in the launch. Despite expected summer seasonality, TONMYA prescriptions grew by 28% in the third quarter and outperformed other FDA-approved fibromyalgia-indicated products in the third quarter, which were generally flat in the same period. Turning to our key performance metrics, third quarter prescriptions totaled 16,375, up 28% from the second quarter. Bridge scripts declined quarter-over-quarter, consistent with significantly more patients moving to covered paid scripts.
New prescriptions grew 17% quarter-over-quarter, and refill prescriptions grew 56% quarter-over-quarter. Our September 1st expansion to 150 sales reps has strengthened the TONMYA business. Total prescriptions, new prescriptions, refills, new writers, and total writers have all meaningfully increased since September 1st compared to the first two months of the third quarter. More field activity, broader and deeper prescriber reach, and sampling are driving the stronger performance. We view these early trends as promising indicators of future performance and are focused on deepening them. Now turning to market access on slide five. TONMYA coverage now reaches approximately 53% of covered lives in the U.S., and we continue to focus on expanding access. We have prioritized access early in the launch to help patients obtain insurance coverage before significantly increasing demand.
We signed multiple commercial and government payer agreements in 2026, including two managed Medicare agreements in the third quarter. Our team is engaging downstream plans under existing agreements and pursuing contracts with additional payers. Since the end of the second quarter, our total prescription approval rate among commercially insured patients has increased, and our bridge prescriptions via BlinkRx, our digital specialty pharmacy, have decreased. Both trends are consistent with expanding coverage, and we expect continued progress. Additionally, prior authorization submission and approval rates remain strong. We recently added third-party field access managers to support further progress. Finally, we added multiple new TONMYA distributors in the third quarter and continue to see stable and consistent days on hand at the large wholesalers. Now looking at marketing, prescriber feedback remains positive. Our latest market research survey of top prescribers shows growing TONMYA awareness.
Since February, unaided awareness of TONMYA has doubled, and more than 80% of healthcare providers surveyed recognized TONMYA when prompted. Intent to prescribe is also encouraging. Our direct-to-consumer, or DTC, initiatives are evolving. We sponsored a segment this morning on "Good Morning America" to help people learn about fibromyalgia, engage with our Move Fibro Forward digital assets, and talk to their providers. On the branded side, in the third quarter, we conducted a media tour with a leading fibromyalgia key opinion leader and paid spokesperson for Tonix. 20 interviews were broadcast across major U.S. markets. On the branded side for HCPs, from September to early November, we generated high-touch engagements through our booth presence and symposia at 13 congresses. KOLs also hosted more than 130 peer-to-peer sessions in the quarter. I will now turn the call back to Seth to discuss medical affairs and our pipeline.
Seth? Thank you, Tom. Our medical affairs organization is focused on building awareness of the TONMYA data that supported FDA approval through participation in key medical meetings.
The team is also educating providers about the current diagnostic criteria for fibromyalgia. The 2016 revised criteria state that fibromyalgia is not a diagnosis of exclusion. The National Academies of Sciences, Engineering, and Medicine has stated that fibromyalgia is a diagnosable condition in long COVID. We believe broader understanding of these criteria could meaningfully grow the diagnosed population and help patients get treated earlier. Now I will move to our priority clinical development programs on slide seven. We are enrolling participants into HORIZON, a phase II potentially pivotal study of TNX-102 SL as a first-line monotherapy in adults with MDD. TNX-102 SL targets the disturbed sleep of depression through antagonism at four neuronal receptors, which we believe represents a novel approach.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
